Lexicon Pharmaceuticals (LXRX) Other Non-Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Other Non-Current Liabilities for 17 consecutive years, with $6.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 20.33% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 20.33% YoY), while the FY2025 annual figure was $7.2 million, up 3.61% from the prior year.
• Other Non-Current Liabilities slipped to $6.4 million in Q1 2026 per LXRX's latest filing, from $7.2 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $7.5 million in Q3 2025 and bottomed at $1.0 million in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $5.4 million across 5 years, with a median of $5.5 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 38.3% — and 2023, when it surged 447.11%.
• Lexicon Pharmaceuticals' Other Non-Current Liabilities stood at $5.4 million in 2022, then retreated by 2.93% to $5.3 million in 2023, then surged by 31.51% to $6.9 million in 2024, then climbed by 3.61% to $7.2 million in 2025, then retreated by 11.05% to $6.4 million in 2026.
• Business Quant data shows LXRX's Other Non-Current Liabilities at $6.4 million in Q1 2026, $7.2 million in Q4 2025, and $7.5 million in Q3 2025.